Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: An epidemiologic perspective

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 363-368

  Brouwers, Frank P ^a   Hillege, Hans L ^a   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Epidemiology; HFpEF; HFrEF; Left ventricular ejection fraction; New onset heart failure; Prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE DISTRIBUTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FOLLOW UP; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; OBESITY; PRIMARY PREVENTION; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE;

COHORT STUDIES; HEART FAILURE; HUMANS; PROGNOSIS; STROKE VOLUME;

EID: 84871238469     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0115-7     Document Type: Review

References (57)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46.
2. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47(5):320-32.
3. Cheng S, Vasan RS. Advances in the epidemiology of heart failure and left ventricular remodeling. Circulation. 2011;124(20):e516-9.
4. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18-28.
5. Shin JJ, Hamad E, Murthy S, Pina IL. Heart failure in women. Clin Cardiol. 2012;35(3):172-7.
6. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162(15):1682-8.
7. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P):P9-16.
8. Dhingra R, Vasan RS. Diabetes and the risk of heart failure. Heart Fail Clin. 2012;8(1):125-33.
9. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305-13.
10. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(3 Suppl):III6-10.
11. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008;52(6):428-34.
12. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9. (Pubitemid 44079340)
13. Kindermann M, Reil JC, Pieske B, van Veldhuisen DJ, Bohm M. Heart failure with normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc Med. 2008;18(8):280-92.
14. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. This study examined trends in prevalence and hospitalization rate for HFpEF versus HFrEF patients. It reported on an increase in hospitalizations for HFpEF, versus a stable hospitalization rate for HFrEF patients.
15. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45.
16. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362 (9386):777-81.
17. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53(23):2150-8.
18. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-Analysis. J Am Coll Cardiol. 2011;57(16):1676-86. This study sought to determine whether pharmacologic interventions changed outcome for HFpEF, in a meta-Analysis. It showed that pharmacotherapy of HFpEF demonstrates a quantifiable improvement in exercise tolerance, but not mortality.
19. Roger VL. The heart failure epidemic. Int J Environ Res Public Health. 2010;7(4):1807-30.
20. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-6.
21. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20(2):301-6.
22. Authors/Task Force Members, McMurray JJ, Adamopoulos S, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14 (8):803-69.
23. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002;162(3):265-70.
24. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628-37.
25. Krumholz HM, Butler J, Miller J, et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation. 1998;97(10):958-64.
26. Hoffman RM, Psaty BM, Kronmal RA. Modifiable risk factors for incident heart failure in the coronary artery surgery study. Arch Intern Med. 1994;154(4):417-23.
27. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699-703.
28. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614-9. (Pubitemid 33716458)
29. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115 (2):173-9. (Pubitemid 46105715)
30. Mokhles MM, Trifiro G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res. 2012;65(3):358-64.
31. Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012;14(4):414-22.
32. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failure among young adults. N Engl J Med. 2009;360(12):1179-90.
33. Husaini BA, Mensah GA, Sawyer D, et al. Race, sex, and age differences in heart failure-related hospitalizations in a southern state: implications for prevention. Circ Heart Fail. 2011;4(2):161-9.
34. Alexander M, Grumbach K, Selby J, Brown AF, Washington E. Hospitalization for congestive heart failure. Explaining racial differences. JAMA. 1995;274(13):1037-42.
35. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22(3):228-36.
36. Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56(21):1712-9.
37. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98(21):2282-9. (Pubitemid 28533847)
38. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20 (6):421-8. (Pubitemid 29116538)
39. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43(3):317-27.
40. Rusinaru D, Leborgne L, Peltier M, Tribouilloy C. Effect of atrial fibrillation on long-Term survival in patients hospitalised for heart failure with preserved ejection fraction. Eur J Heart Fail. 2008;10 (6):566-72.
41. Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012. This cohort from the Framingham Heart Study is one of the few with data on new onset HFrEF and HFpEF, in a community-based population. It shows several different pre-onset and clinical characteristics at the time of heart failure presentation.
42. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119 (24):3070-7.
43. Chinali M, Joffe SW, Aurigemma GP, et al. Risk factors and comorbidities in a community-wide sample of patients hospitalized with acute systolic or diastolic heart failure: the Worcester Heart Failure Study. Coron Artery Dis. 2010;21(3):137-43.
44. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis. 2011;54(2):144-53.
45. Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail. 2011;17(1):31-8.
46. Liu M, Chan CP, Yan BP, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2012;14(1):39-44.
47. Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58(1):47-55.
48. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497-505.
49. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107-15.
50. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J. 2001;22(15):1318-27.
51. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505-10.
52. Levy D, Kenchaiah S, Larson MG, et al. Long-Term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402.
53. Rickenbacher P, Pfisterer M, Burkard T, et al. Why and how do elderly patients with heart failure die? Insights from the TIMECHF study. Eur J Heart Fail. 2012.
54. Hamaguchi S, Kinugawa S, Sobirin MA, et al. Mode of death in patients with heart failure and reduced vs. Preserved ejection fraction. Circ J. 2012;76(7):1662-9.
55. Velagaleti RS, Gona P, Larson MG, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010;122(17):1700-6.
56. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. 2008;1(2):125-33.
57. Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. Am Heart J. 2011;162(2):246-53.